Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DICLOFENAC vs ACETAMINOPHEN AND IBUPROFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diclofenac inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.
Ankylosing spondylitis,Osteoarthritis,Rheumatoid arthritis,Acute migraine (oral formulation),Mild to moderate acute pain (off-label),Dysmenorrhea (off-label)
Temporary relief of minor aches and pains,Reduction of fever,Off-label: Management of osteoarthritis pain, headache, dysmenorrhea
Oral: 50 mg twice daily or 75 mg twice daily; maximum 150 mg/day. Topical: apply 4 times daily. IM: 75 mg once daily.
Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.
Terminal elimination half-life ~2 h (diclofenac immediate-release); enterohepatic recirculation may produce secondary peaks. Clinical context: Short half-life requires multiple daily dosing for sustained effect.
Acetaminophen: 2-3 hours (normal hepatic function). Ibuprofen: 2-4 hours (immediate-release); prolonged in overdose or hepatic impairment.
Primarily hepatic via CYP2C9 (major) and CYP3A4 (minor); undergoes glucuronidation. Metabolites include 4'-hydroxydiclofenac, 5-hydroxydiclofenac, and 3'-hydroxydiclofenac.
Acetaminophen is primarily metabolized via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a toxic metabolite, NAPQI. Ibuprofen is metabolized primarily by CYP2C9 and to a lesser extent by CYP2C8.
Renal (65% as metabolites, <1% unchanged); biliary/fecal (35% as metabolites).
Acetaminophen: renal excretion of metabolites (glucuronide 55%, sulfate 30%, cysteine/mercapturate <10%); <5% unchanged. Ibuprofen: renal excretion of metabolites (conjugates) 90%; <10% unchanged; minor biliary/fecal.
>99% bound primarily to serum albumin.
Acetaminophen: 10-25% (albumin). Ibuprofen: >99% (albumin).
0.1-0.2 L/kg (low distribution, reflects high protein binding). Clinical meaning: Limited extravascular distribution; primarily remains in vascular space.
Acetaminophen: 0.9 L/kg; Ibuprofen: 0.15 L/kg (highly protein-bound, low Vd).
Oral immediate-release: ~50% due to extensive first-pass metabolism; Topical: <10% systemic; Ophthalmic: minimal; IV: 100%.
Acetaminophen: 75-85% oral. Ibuprofen: 80-100% oral.
GFR >30 m L/min: no adjustment. GFR 15-30 m L/min: use with caution, reduce dose, avoid if possible. GFR <15 m L/min: contraindicated.
GFR 30-59: Caution, use lowest effective dose; GFR <30: Contraindicated due to ibuprofen component.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Child-Pugh A: No adjustment; Child-Pugh B: Caution, reduce acetaminophen dose; Child-Pugh C: Contraindicated.
Children ≥1 year: oral 0.5-1 mg/kg/dose twice daily; maximum 3 mg/kg/day or 150 mg/day. Children ≥14 years: same as adult.
Weight-based: 10-15 mg/kg acetaminophen + 5-10 mg/kg ibuprofen per dose, every 6-8 hours, max 4 doses/day.
Start at lowest effective dose, e.g., 25-50 mg/day oral; increase cautiously. Avoid NSAIDs in advanced age due to GI and renal risks.
Use lowest effective dose; monitor renal function due to ibuprofen; avoid durations >10 days.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Diclofenac is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Acetaminophen may cause severe liver injury, including acute liver failure, at doses exceeding 4,000 mg/day. Ibuprofen: NSAIDs increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. NSAIDs also increase risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines.
Cardiovascular risk: increased risk of thrombotic events, hypertension, and heart failure.,Gastrointestinal risk: increased risk of serious GI adverse events including bleeding, ulceration, and perforation.,Renal toxicity: monitor renal function in patients with preexisting renal disease, dehydration, or concomitant nephrotoxic agents.,Hepatic toxicity: elevated liver enzymes; rare cases of severe hepatic reactions.,Anaphylactoid reactions: can occur in patients with or without known NSAID hypersensitivity.,Fluid retention and edema: use with caution in patients with hypertension or heart failure.,Skin reactions: serious cutaneous adverse reactions such as Stevens-Johnson syndrome and DRESS.,Hematologic: prolonged bleeding time; use with caution in patients with coagulation disorders.
Acetaminophen: Hepatotoxicity risk with excessive doses, use with caution in hepatic impairment, avoid with alcohol use >3 drinks/day. Ibuprofen: Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, avoid late pregnancy.
Known hypersensitivity to diclofenac or any component of the formulation,History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs,Perioperative pain in the setting of CABG surgery,Active GI bleeding,Severe uncontrolled heart failure,Advanced renal disease (unless dialysis is ongoing),Third trimester of pregnancy
Acetaminophen: Severe hepatic impairment, allergy to acetaminophen. Ibuprofen: Hypersensitivity to ibuprofen or other NSAIDs, history of asthma/urticaria after NSAIDs, perioperative pain in CABG surgery, severe heart failure, active GI bleeding, late pregnancy.
Avoid alcohol as it increases risk of GI bleeding. Take with food or milk to minimize GI irritation. No specific food restrictions, but high-fat meals may delay absorption.
Avoid alcohol; take with food or milk to minimize GI irritation. No specific food restrictions.
First trimester: Increased risk of spontaneous abortion and congenital malformations (cardiac defects, gastroschisis) due to prostaglandin synthesis inhibition. Second trimester: Risk of oligohydramnios and fetal renal impairment with prolonged use. Third trimester: Avoid after 30 weeks gestation; risk of premature closure of ductus arteriosus, persistent pulmonary hypertension of the newborn, and oligohydramnios.
First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibuprofen is relatively safe but may cause oligohydramnios. Third trimester: Acetaminophen is safe; ibuprofen is contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Excreted in breast milk in low amounts; M/P ratio not reported. Use with caution; avoid in breastfeeding mothers with infants with thrombocytopenia or platelet dysfunction. Consider risk of infant renal impairment.
Acetaminophen: low levels in breast milk, M/P ratio ~0.9; considered compatible with breastfeeding. Ibuprofen: minimal excretion, M/P ratio ~0.01; considered compatible. Combination: low risk with recommended doses.
No dose adjustment recommended for pharmacokinetic changes; however, use at lowest effective dose for shortest duration. Avoid in third trimester due to fetal risks. Consider alternative analgesics in all trimesters.
No standard adjustment for acetaminophen; ibuprofen dosing unchanged in pregnancy but avoid in third trimester; consider increased clearance of acetaminophen in pregnancy but no dose adjustment recommended.
Diclofenac is a potent NSAID with a short half-life, making it suitable for acute pain but requiring frequent dosing. It carries a higher risk of cardiovascular events compared to other NSAIDs; caution in patients with hypertension or heart disease. Enteric-coated formulations may delay onset but reduce GI irritation. Intravenous formulation allows for rapid analgesia but requires monitoring for hypertension and fluid retention. Diclofenac can cause elevation of liver enzymes; monitor LFTs with long-term use. It is available in combination with misoprostol to reduce GI ulcer risk.
Combination product for acute pain; fixed-dose may exceed recommended daily acetaminophen limit if other acetaminophen-containing products are used. Onset of ibuprofen is 30-60 min, acetaminophen 15-30 min; duration 4-6 hours. Caution in renal impairment (ibuprofen) and hepatic impairment (acetaminophen). Avoid in third trimester of pregnancy.
Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication to lower risk of stomach bleeding.,Do not take with other NSAIDs (e.g., ibuprofen, naproxen) or aspirin without consulting doctor.,Report signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds) or chest pain immediately.,May cause dizziness or drowsiness; avoid driving until you know how this drug affects you.,Limit sun exposure and use sunscreen as this drug may increase sun sensitivity.,Do not use in third trimester of pregnancy as it may harm the unborn baby.,Store at room temperature away from moisture and heat.
Do not exceed 10 tablets (500 mg acetaminophen/200 mg ibuprofen) per day.,Do not take with other products containing acetaminophen or NSAIDs.,Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication.,Seek medical help if pain persists >10 days or fever >3 days.,Store at room temperature, away from moisture.
"Ximelagatran, an oral direct thrombin inhibitor, increases the risk of bleeding when coadministered with diclofenac, a nonsteroidal anti-inflammatory drug (NSAID). The combination potentiates anticoagulant activity through additive inhibition of platelet aggregation and thrombin-mediated coagulation, elevating the risk of gastrointestinal hemorrhage and other serious bleeding events. Patients, particularly those with renal impairment or advanced age, require close monitoring for signs of bleeding."
"Acebutolol, a cardioselective beta-blocker, may attenuate the antihypertensive effect of diclofenac, a nonsteroidal anti-inflammatory drug (NSAID). Diclofenac inhibits cyclooxygenase, reducing prostaglandin synthesis, which can lead to sodium retention and increased vascular resistance, thereby counteracting the blood pressure-lowering effects of acebutolol. This interaction may result in diminished blood pressure control, potentially requiring dose adjustments of antihypertensive therapy."
"Enzalutamide, a potent CYP3A4 inducer, significantly reduces the exposure of diclofenac, a CYP2C9 substrate, by increasing its hepatic metabolism. This interaction can lead to subtherapeutic diclofenac concentrations, thereby diminishing its analgesic and anti-inflammatory efficacy. Clinically, patients may experience inadequate pain control or exacerbation of inflammatory conditions, such as arthritis, when these agents are coadministered."
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DICLOFENAC vs ACETAMINOPHEN AND IBUPROFEN, answered by our medical review team.
DICLOFENAC is a NSAID that works by Diclofenac inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.. ACETAMINOPHEN AND IBUPROFEN is a NSAID that works by Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DICLOFENAC and ACETAMINOPHEN AND IBUPROFEN depend on the specific clinical indication. These are both NSAID agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DICLOFENAC is: Oral: 50 mg twice daily or 75 mg twice daily; maximum 150 mg/day. Topical: apply 4 times daily. IM: 75 mg once daily.. The standard adult dose of ACETAMINOPHEN AND IBUPROFEN is: Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DICLOFENAC and ACETAMINOPHEN AND IBUPROFEN. The risk or severity of adverse effects can be increased when Diclofenac is combined with Ibuprofen. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DICLOFENAC is classified as Category D/X. First trimester: Increased risk of spontaneous abortion and congenital malformations (cardiac defects, gastroschisis) due to prostaglandin synthesis inhibition. Second trimester: R. ACETAMINOPHEN AND IBUPROFEN is classified as Category D/X. First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibup. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.